Swiss stocks - Factors to watch on April 26
ZURICH, April 26 The Swiss blue-chip SMI was seen opening 0.12 percent higher at 8,786 points on Wednesday, according to premarket indications by bank Julius Baer.
Jan 12 Pluristem Therapeutics Inc
* Pluristem completes patient enrollment in a large multinational phase II trial in intermittent claudication
* Expect to report top line results in early 2018 for phase II IC trial
* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage:
* Board chairs must help oversee change, era of easy growth over